About the speaker
Aimee Edinger is an Associate Professor of Developmental and Cell Biology in the UC Irvine School of Biological Sciences and a member of the NCI-designated Chao Family Comprehensive Cancer Center at UCI.
She joined UCI in 2005 after completing a PhD in Virology, veterinary training (VMD), and a postdoctoral fellowship in Cancer Metabolism at the University of Pennsylvania in Philadelphia.
Her lab studies the mechanisms by which normal and transformed cells acquire nutrients with the goal of developing novel therapeutics targeting these pathways. In collaboration with synthetic chemist Stephen Hanessian, she has developed an orally bioavailable small molecule sphingolipid-mimetic that disrupts cellular access to glucose, amino acids, and lipids. This compound is currently in pre-clinical development by a start-up company they co-founded. Small molecule inhibitors of macropinocytosis are also under study. Edinger lab research in leukemia, prostate, and breast cancer models has been funded by the National Cancer Institute, the National Institute of General Medical Sciences, the American Cancer Society, the Department of Defense’s Congressionally Directed Medical Research Program, the University of California Cancer Research Coordinating Committee, the Gabrielle’s Angel Foundation, the William Lawrence and Blanche Hughes Foundation, the UCI Chao Family Comprehensive Cancer Center, the Anti-Cancer Challenge, and UCI Applied Innovation.
Dr. Aimee Edinger is an inventor on four patents with others in process.
Seminar starts at 4pm, followed by drinks and nibbles at 5pm
More info: Professor Nigel Turner, Deputy Director of Research, SoMS UNSW Sydney email@example.com